Clinical staging of hepatocellular carcinoma

Digestive Diseases

Volumn 27, Issue 2, 2009, Pages 131-141

  Meier, Volker ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Barcelona Clinic Liver Cancer; Cancer of the Liver Italian Program; DNA microarray; Hepatocellular carcinoma; Japan Integrated Staging; Prognostic scores

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER;

CANCER CLASSIFICATION; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; DECOMPENSATED LIVER CIRRHOSIS; DNA MICROARRAY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER SURGERY; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; VALIDITY;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MICROARRAY ANALYSIS; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 67650938568     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218345     Document Type: Review

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan2000. Int J Cancer 2001;94:153156.
2. McGlynn KA, Tsao L, Hsing AW, Devesa SS,Fraumeni JF Jr: International trends and patterns of primary liver cancer. Int J Cancer2001;94: 290296.
3. Lau WY, Lai EC: Hepatocellular carcinoma:current management and recent advances.Hepatobiliary Pancreat Dis Int 2008; 7:237257.
4. Calle EE, Teras LR, Thun MJ: Obesity andmortality. N Engl J Med 2005; 353:21972199.
5. Okuda K, Ohtsuki T, Obata H, TomimatsuM, Okazaki N, Hasegawa H, Nakajima Y,Ohnishi K: Natural history of hepatocellularcarcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918928.
6. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C: A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carci nome Hepatocellulaire. J Hepatol 1999;31:133141.
7. Leung TW, Tang AM, Zee B, Lau WY, Lai PB,Leung KL, Lau JT, Yu SC, Johnson PJ: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system,the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002;94:17601769.
8. The Cancer of the Liver Italian Program(CLIP) Investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology1998;28:751755.
9. The Cancer of the liver Italian Program(CLIP) Investigators: Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellu lar carcinoma. Hepatology 2000; 31:840845.
10. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329338.
11. Kitai S, Kudo M, Minami Y, Ueshima K,Chung H, Hagiwara S, Inoue T, Ishikawa E,Takahashi S, Asakuma Y, Haji S, Osaki Y,Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan Integrated Staging score. Intervirology 2008;51(suppl 1):8694.
12. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma(CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterol 2003;38: 207215.
13. Tateishi R, Yoshida H, Shiina S, Imamura H,Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Makuuchi M, Omata M: Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54:419425.
14. Yau T, Yao TJ, Chan P, Ng K, Fan ST, Poon RT: A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy:implication for patient selection in systemictherapy trials. Cancer 2008;113:27422751.
15. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:19071917.
16. Marrero JA, Fontana RJ, Barrat A, Askari F,Conjeevaram HS, Su GL, Lok AS: Prognosis of hepatocellular carcinoma: comparison of seven staging systems in an American cohort. Hepatology 2005; 41: 707716.
17. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42:12081236.
18. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421430.
19. Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T: Comparison of three current staging systems for hepatocel lular carcinoma: Japan Integrated Staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol 2008;23:445 452.
20. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:13961405.
21. Toyoda H, Kumada T, Kiriyama S, Sone Y,Tanikawa M, Hisanaga Y, Yamaguchi A,Isogai M, Kaneoka Y, Washizu J: Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC,and JIS) in Japan. Am J Gastroenterol 2005;100:17641771.
22. Camma C, Di Marco V, Cabibbo G, Latteri F,Sandonato L, Parisi P, Enea M, Attanasio M,Galia M, Alessi N, Licata A, Latteri MA,Craxi A: Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008; 28: 6275.
23. Huo TI, Hsia CY, Huang YH, Lin HC, Lee PC, Lui WY, Chiang JH, Chiou YY, Loong CC, Lee SD: Selecting a shortterm prognostic model for hepatocellular carcinoma:comparison between the model for endstageliver disease (MELD), MELDsodium, and five cancer staging systems. J Clin Gastroen terol 2009 (in press).
24. Lu W, Dong J, Huang Z, Guo D, Liu Y, Shi S: Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Oku da, CLIP, TNM and CUPI. J Gastroenterol Hepatol 2008; 23: 18741878.
25. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G: Prognostic factors for survival in patients with earlyintermediate hepatocellular carcinoma undergoing nonsurgical therapy:comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut2005;54:411418.
26. Tandon P, GarciaTsao G: Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009;2 9:502510.
27. Schena M, Shalon D, Davis RW, Brown PO:Quantitative monitoring of gene expression atterns with a complementary DNA micro rray. Science 1995;270:467470.
28. Lau WY, Lai PB, Leung MF, Leung BC, Wong, Chen G, Leung TW, Liew CT: Differential ene expression of hepatocellular carcinoma sing cDNA microarray analysis. Oncol Res2000;12:5969.
29. Wang XW, Thorgeirsson SS: Transcriptome nalysis of liver cancer: ready for the clinic? J Hepatol 2009;50:10621064.
30. KaposiNovak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Conner EA, Factor VM, Ros kams T, Thorgeirsson SS: Central role of c Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009; 69:27752782.
31. Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ, Thorgeirsson SS: Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 2009;69: 40594066.
32. Wang W, Peng JX, Yang JQ, Yang LY: Identification of gene expression profiling in hepa tocellular carcinoma using cDNA microar rays. Dig Dis Sci 2009 (in press).
33. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, Shen F, Tang ZY, Wang XW: Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 2007; 13: 11331139.
34. Yoshioka S, Takemasa I, Nagano H, Kittaka N, Noda T, Wada H, Kobayashi S, Marubashi S, Takeda Y, Umeshita K, Dono K, Matsuba ra K, Monden M: Molecular prediction of early recurrence after resection of hepatocel lular carcinoma. Eur J Cancer 2009; 45:881- 889.
35. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J,Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Wata nabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazza ferro V, Bruix J, Friedman SL, Kumada H,Llovet JM, Golub TR: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 19952004.
36. Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, Kim W, Park SC, Chung YJ, Kim BG, Yoon JH, Lee HS, Kim CY, Yi NJ, Suh KS, Lee KU, Chu IS, Roskams T, Thorgeirsson SS, Kim YJ: Gene expressionbased recurrence prediction of hepatitis B virusrelated human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 20562064.
37. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H: Aurora kinase B is a predictive factor for the aggressive recurrence of hepa tocellular carcinoma after curative hepatec tomy. Br J Surg 2008; 95: 611619.
38. Yasen M, Mizushima H, Mogushi K, Obul hasim G, Miyaguchi K, Inoue K, Nakahara I, Ohta T, Aihara A, Tanaka S, Arii S, Tanaka H: Expression of aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci 2009; 100:472480.
39. Iizuka N, Hamamoto Y, Tsunedomi R, Oka M: Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Sci 2008; 99:659665.
40. Nakata T, Seki N, Miwa S, Kobayashi A, Soe da J, Nimura Y, Kawasaki S, Miyagawa S: Identification of genes associated with multiple nodules in hepatocellular carcinoma using cDNA microarray: multicentric occurrence or intrahepatic metastasis? Hepa togastroenterology 2008; 55: 865872.